09 August 2024
Oxford Nanopore Technologies
plc
Director
Declaration
Pursuant to Listing Rule 6.4.9 R(2),
Oxford Nanopore Technologies plc (the "Company") confirms that
Heather Preston, Non-Executive Director of the Company, was
appointed to the Board of Aligos Therapeutics (Nasdaq: ALGS) as
Non-Executive Director effective 7 August 2024.
[ENDS]
For further information, please
contact:
Oxford Nanopore Technologies plc
Investors:
ir@nanoporetech.com
Media:
media@nanoporetech.com
Teneo (communications adviser to the
Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal
is to bring the widest benefits to society through enabling the
analysis of anything, by anyone, anywhere. The company has
developed a new generation of nanopore-based sensing technology
that is currently used for real-time, high-performance, accessible,
and scalable analysis of DNA and RNA. The technology is used
in more than 120 countries, to understand the biology of humans,
plants, animals, bacteria, viruses and environments as well as to
understand diseases such as cancer. Oxford Nanopore's technology
also has the potential to provide broad, high impact, rapid
insights in a number of areas including healthcare, food and
agriculture.
Oxford Nanopore devices sequence DNA
and RNA directly and sequence short to ultra-long fragments of DNA,
for a truly comprehensive picture of the genome. Data is streamed
in real-time and can enable rapid insights. The technology is
fully scalable - from pocket-sized to ultra-high throughput
devices.
For more information please
visit: www.nanoporetech.com